Submission Deadline: 31 January 2024 (Status: Open)
Special Issue Editor
Dr. Kok-Lun Pang
Email
|
Website 1
|
Website 2
Newcastle University Medicine Malaysia, Iskandar Puteri, Malaysia
Interests:
apoptosis study; cancer signaling; carcinogenesis; pharmacognosy; toxicology
Special Issue Information
Dear Colleagues,
In 2019, the number of bone fractures was estimated at 178 million new cases and 455 million prevalent bone fractures worldwide. Aside from trauma, primary bone diseases including osteoporosis, osteopenia, osteoarthritis, osteomalacia and cancer-related bone disease are greatly contributing to bone fracture. Several pharmacological agents from natural or chemical synthesis have been developed as the first line of treatment or disease-modifying drugs. Nevertheless, the upstream molecular mechanisms of some of these drugs remain undetermined. The molecular understanding of these drugs is essential to identify novel molecular targets for new drug therapies.
Thus, we encourage all researchers working on this topic to submit research articles or reviews on the molecular pharmacology of bone diseases, including but not limited to osteoporosis, osteoarthritis, and osteosarcoma. Any relevant pre-clinical or clinical studies on pharmacological agents like bioactive compounds, biologics, immunotherautic agents, nanoparticles or semi-synthetic or synthetic drugs are welcome. Treatment-induced bone diseases will also be considered. However, we do not encourage the study with cruel extract or its molecular pharmacology aspect is not determined.
Kok-Lun Pang
Guest Editor
Keywords
drug targets; exosome; immunotherapy; nanoparticle; osteoarthritis; osteoporosis; osteosarcoma; pharmacognosy
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://www.biolifesas.org/journalx_brha/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.
